Kamstrup PR, et al. JAMA 2009; 301:

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

European Heart Journal 2010; 31:

Clinical Outcomes with Newer Antihyperglycemic Agents

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Introduction Lipoprotein(a) [Lp(a)]

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.

Date of download: 9/19/2016 From: Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease:

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Fig. 1. Mean plasma lipid and lipoprotein levels as a function of the common genetic variants in LCAT, g.-293G>A, S208T, and L369L in the CCHS and S208T.

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening by Kasper Aalbæk Kjærgaard, Morten.

Baseline characteristics of patients

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Plasma 25-Hydroxyvitamin D and Risk of Non-Melanoma and Melanoma Skin Cancer: A Prospective Cohort Study Shoaib Afzal, Børge G. Nordestgaard, Stig E.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Fung TT, et al. Circulation 2009;119:

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

David J.A. Jenkins et al. JACC 2018;71:

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Association between white matter integrity and global neurocognitive impairment. Association between white matter integrity and global neurocognitive impairment.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Study Participant Flow

Flow Diagram of the Trial Selection Process

Baseline Characteristics of the Study Participants

(A) Meta-analysis of repeat revascularisation in randomised trials.

Baseline Characteristics

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Dennis G. Moledina, MD, Mark A. Perazella, MD

Collet JP, et al. Lancet 2009;373:309-17

Study Flow Diagram Thompson A, et al. JAMA 2008;299:

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.

Sotirios Tsimikas JACC 2017;69:

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

The ACCORD Study Group. NEJM 2010; Epub March 14

Potential effect of guidelines on ASCVD prevention in the CGPS*

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Lifetime heart failure risk*

Year-wise trends in MRRUF

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Forest plot illustrating the risk ratio of myocardial infarction

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Presentation transcript:

Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Basic Characteristics of Participants (White Individuals of Danish Descent) in the 3 Studies Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Baseline Cardiovascular Risk Factors by Genotype for Participants in the Copenhagen City Heart Studya Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Risk of Myocardial Infarction by Extreme Levels of Lipoprotein(a) in the General Population Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Mean Lipoprotein(a) Levels in the CCHS as a Function of Octiles or Quartiles of Apolipoprotein(a) KIV-2 Repeats P values are for Cuzick nonparametric test for trend of mean lipoprotein(a) levels. Participants in the 1991-1994 or 2001-2003 examination were included (n=9867). CCHS indicates Copenhagen City Heart Study; KIV-2, kringle IV type 2. Error bars indicate 95% confidence intervals Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Lipoprotein(a) Levels as a Function of Kringle IV Type 2 Repeats in the Copenhagen City Heart Studya Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Risk of Myocardial Infarction by Quartiles of Apolipoprotein(a) KIV-2 Repeats in the CCHS, CGPS, and CIHDS Kamstrup PR, et al. JAMA 2009; 301:2331-2339

Risk of Myocardial Infarction for Doubling in Lipoprotein(a) Levels in the CCHS Kamstrup PR, et al. JAMA 2009; 301:2331-2339